Literature DB >> 23425082

Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy.

Lokesh Jain1, Barjesh Chander Sharma, Siddharth Srivastava, Sunil Kumar Puri, Praveen Sharma, Shiv Sarin.   

Abstract

BACKGROUND: Minimal hepatic encephalopathy (MHE) represents the mildest form of hepatic encephalopathy (HE), with abnormal neuropsychologic findings. Inflammatory response may be important in the pathogenesis of MHE. On magnetic resonance spectroscopy (MRS), improvement of metabolic ratios after liver transplantation suggests an important role of myoinositol (mI) and choline (cho) in the development of MHE. AIMS: To investigate arterial ammonia, tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, IL-18, serum endotoxin, and MRS before and after treatment in MHE. PATIENTS AND METHODS: Sixty patients of cirrhosis with MHE were randomized to two groups, Gr. MHE-L (n = 30), treated with lactulose for 3 months, and Gr. MHE-NL (n = 30), who did not received lactulose. Arterial ammonia, TNF-α, IL-6, IL-18, serum endotoxin, and MRS were performed in all patients at baseline and at 3 months and 20 patients of cirrhosis without MHE and 20 healthy controls.
RESULTS: After 3 months, median arterial ammonia (69.4 vs 52.7 mcg/dL), TNF-α (26.6 vs 22 pg/mL), IL-6 (17.6 vs 12.4 pg/mL), IL-18 (42.5 vs 29 pg/mL), and serum endotoxin (0.68 vs 0.43 EU/mL) significantly decreased in Gr. MHE-L compared with baseline (P < 0.0001), while no change was seen in Gr. MHE-NL patients. On MRS, compared with patients of cirrhosis without MHE, mI and cho were significantly lower (P < 0.001) and glutamine (Glx) was significantly higher in both MHE groups (P < 0.001). After 3 months, mI and cho increased and Glx decreased significantly in Gr. MHE-L (P < 0.001), without changes in Gr. MHE-NL patients. Psychometric hepatic encephalopathic score (PHES) correlated well with arterial ammonia, TNF-α, IL-6, IL-18, serum endotoxin, and metabolic parameters on MRS.
CONCLUSIONS: Arterial ammonia, inflammatory mediators (TNF-α, IL-6, IL-18), and serum endotoxin reduce and MRS abnormalities improve after treatment with lactulose in patients with MHE.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23425082     DOI: 10.1111/jgh.12160

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  24 in total

Review 1.  Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis.

Authors:  Ming Luo; Jian-Yang Guo; Wu-Kui Cao
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

2.  Factors contributing to the development of overt encephalopathy in liver cirrhosis patients.

Authors:  Motoh Iwasa; Ryosuke Sugimoto; Rumi Mifuji-Moroka; Nagisa Hara; Kyoko Yoshikawa; Hideaki Tanaka; Akiko Eguchi; Norihiko Yamamoto; Kazushi Sugimoto; Yoshinao Kobayashi; Hiroshi Hasegawa; Yoshiyuki Takei
Journal:  Metab Brain Dis       Date:  2016-06-29       Impact factor: 3.584

Review 3.  Management of covert hepatic encephalopathy.

Authors:  Abhijeet Waghray; Nisheet Waghray; Kevin Mullen
Journal:  J Clin Exp Hepatol       Date:  2014-04-01

Review 4.  Gut microbiota: its role in hepatic encephalopathy.

Authors:  Rahul Rai; Vivek A Saraswat; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12-16

Review 5.  Diagnosis of minimal hepatic encephalopathy.

Authors:  Karin Weissenborn
Journal:  J Clin Exp Hepatol       Date:  2014-07-31

6.  Update in Hepatic Encephalopathy.

Authors:  Madhumita Premkumar; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2018-10-04

Review 7.  Pathogenesis of Hepatic Encephalopathy in Chronic Liver Disease.

Authors:  Rafael Ochoa-Sanchez; Christopher F Rose
Journal:  J Clin Exp Hepatol       Date:  2018-08-18

Review 8.  The role of microbiota in hepatic encephalopathy.

Authors:  Jasmohan S Bajaj
Journal:  Gut Microbes       Date:  2014-04-01

Review 9.  Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.

Authors:  Lise Lotte Gluud; Hendrik Vilstrup; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2016-05-06

Review 10.  Disaccharides in the treatment of hepatic encephalopathy.

Authors:  Praveen Sharma; Barjesh Chander Sharma
Journal:  Metab Brain Dis       Date:  2013-03-02       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.